Skip to content

Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice)

Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07575789
Acronym
AHJ
Enrollment
24
Registered
2026-05-08
Start date
2023-03-03
Completion date
2023-04-04
Last updated
2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaundice

Keywords

Grape (VITIS VINIFERA) Seed Powder and Vitamin C

Brief summary

Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.

Detailed description

According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week). According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.

Interventions

DIETARY_SUPPLEMENTGrape-C supplement

Grape-C supplement purchased from Nutrifactor brand.

Sponsors

University of Lahore Hospital (ULH)
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Both men and women * Participants between the ages of 20-40 years will be included * Patients having signs and symptoms of acquired hepatic jaundice * Patients having high serum bilirubin, albumin, ALT, AST, ALP levels * The patient having ALT level more than 10-50 U/L were included * The participants having AST level above than 0-40 IU/L were included in this study * Patients having ALP level more than 30 - 130 U/L were included in this research study * Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation * Participants having the range of albumin more than 30-50 g/L were included in this research * Participants those were underweighted were included

Exclusion criteria

* Patients who already taking any supplement or medication * Participants taking any anti-inflammatory medications * People who were suffering from any other disease * Patients who have any known allergies * Non willing patients * Lactating women * Pregnant women * Smokers

Design outcomes

Primary

MeasureTime frameDescription
Bilirubin levels4 weeksIn this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group

Countries

Pakistan

Contacts

STUDY_CHAIRDr Habib-ur-Rehman Rehman, PhD Food and Nutrition

University of Lahore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026